Kisqali shows clinically meaningful overall survival benefit in broad HR+/HER2- early breast cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Novartis Pharma AG Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3 Patients off Kisqali for a median of three years, with clinical benefit…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishSix-year NATALEE data strengthens Novartis' Kisqali positioning in a large oncology segment.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novartis announced results from the six-year follow-up of the Phase III NATALEE trial.
- 02Kisqali plus endocrine therapy reduces the risk of death by about 20% versus endocrine therapy alone.
- 03The population includes stage II and III HR+/HER2- patients at high risk of recurrence.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Novartis AG156.27 USDMarket closedtoday +1.52%Positive Novartis AG128.28 CHF-0.12%today -0.47%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets